Johnson & Johnson reported solid Q3 results, raising EPS guidance and showing resilience despite generic competition impacting some pharmaceutical sales. Strong growth in consumer and medical devices segments, effective cost-saving measures, and a robust pipeline indicate positive short-term momentum. Therefore, the stock is likely to experience a positive impact in the next 1â€“2 weeks.

[1]